Lastest Stories by Jon C. Ogg

The top analyst upgrades, downgrades and initiations on Friday included Apple, Broadcom, Charter Communications, Comcast, CommScope, Consolidated Edison, Next Era Energy, Rockwell Automation and...
Five of the 30 Dow Jones industrials are down so far in 2019, and some more are literally just one bad day away from being down for the year.
Some investors believe that the transportation stocks have to do well for the stock market to do well. After all, if people and goods are not being transported around the country and the globe then...
24/7 Wall St. has identified 10 technology stocks from the S&P 500 that would be considered cheap on forward earnings multiples, come with upside to the consensus price targets and offer solid...
Even with indexes back within striking distance of their all-time highs. Some investors remain quite cautious and are looking for cheaper stocks with more predictable earnings, dividend yields and...
The Russell indexes are rebalanced each year, and the latest preliminary rebalance was announced recently. These changes create many inflows and outflows of shares from funds.
The top analyst upgrades, downgrades and initiations on Thursday included Abbott Laboratories, CenterPoint Energy, Dominion Energy, Delphi Technologies, Dollar General, Lennar, Lululemon Athletica,...
State Street had to worry about the yield curve after all. The trust and custodial bank has warned that second-quarter net interest income will fall short of expectations.
Whether you were in favor of or against the Affordable Care Act, it is likely of little surprise that the cost of health care has continued to rise. What also has risen handily is the number of...
Luckin Coffee has seen its post-IPO quiet period come to an end, and Wall Street analysts from its underwriting syndicate are now free to cover the stock with research reports.
When investors and economists see that the Consumer Price Index barely rose in May, they probably want to shrug, even if prices for the shelter and food indexes increased.
Stocks took a breather on Wednesday morning, a move that may continue this week’s idea that the snapback rally was too quick and went too far. With so many developments and so many sidebar issues...
One relatively small clinical-stage biopharmaceutical player called Global Blood Therapeutics may be about to change how sickle cell disease treatment goes.